BTA-9881

CAS No. 1646857-24-0

BTA-9881( —— )

Catalog No. M34195 CAS No. 1646857-24-0

BTA-9881 is a novel RSV fusion inhibitor with oral activity and antiviral activity for the study of respiratory syncytial virus infections.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 372 In Stock
10MG 635 In Stock
25MG 1387 In Stock
50MG 1841 In Stock
100MG 2483 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BTA-9881
  • Note
    Research use only, not for human use.
  • Brief Description
    BTA-9881 is a novel RSV fusion inhibitor with oral activity and antiviral activity for the study of respiratory syncytial virus infections.
  • Description
    BTA-9881 is a novel RSV fusion inhibitor with oral activity and antiviral activity for the study of respiratory syncytial virus infections.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    JAK/STAT Signaling
  • Target
    STAT
  • Recptor
    RSV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1646857-24-0
  • Formula Weight
    390.82
  • Molecular Formula
    C21H15ClN4O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(=O)(N1[C@]2(C=3C(C(=O)N2CC1)=CC=NC3)C4=CC=C(Cl)C=C4)C=5C=CC=NC5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Fludarabine

    Fludarabine(NSC 118218), a DNA synthesis inhibitor.

  • Stafia-1

    Stafia-1 is a potent STAT5a inhibitor ( IC50=22.2 μM). Stafia-1 displays high selectivity over STAT5b and other STAT family members.

  • Palivizumab

    Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).